Propacetamol hydrochloride

Synonyms: 盐酸丙帕他莫
Propacetamol hydrochloride 是一种口服有效的对乙酰氨基酚前体及急性肝损伤模型诱导剂,具有抗伤害感受、抗氧化和胃保护等多重特性,可增强 Tramadol 并减轻 Aspirin (MS-D43752) 诱导的胃黏膜损伤及脂质过氧化,在特定条件下也可作为肝毒性诱导剂引发急性肝损伤、氧化应激及细胞凋亡且其毒性敏感性存在品系差异,可用于急性肝损伤、药物性肝毒性以及胃黏膜损伤的研究。
产品编号: MS-H99489 纯度: 99.74% CAS No.: 66532-86-3 分子式: C14H21ClN2O3 分子量: 300.78
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
250mg
询价
3-5 天
500mg
询价
询价
1g
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Propacetamol hydrochloride 是一种口服有效的对乙酰氨基酚前体及急性肝损伤模型诱导剂,具有抗伤害感受、抗氧化和胃保护等多重特性,可增强 Tramadol 并减轻 Aspirin (MS-D43752) 诱导的胃黏膜损伤及脂质过氧化,在特定条件下也可作为肝毒性诱导剂引发急性肝损伤、氧化应激及细胞凋亡且其毒性敏感性存在品系差异,可用于急性肝损伤、药物性肝毒性以及胃黏膜损伤的研究。

生物实验数据

生物活性 Propacetamol hydrochloride is an orally effective acetaminophen prodrug and an acute liver injury model inducer with multiple properties including antinociceptive, antioxidant, and gastroprotective effects; it potentiates Tramadol and attenuates Aspirin (MS-D43752)-induced gastric mucosal damage and lipid peroxidation, and under specific conditions can also act as a hepatotoxic inducer to trigger acute liver injury, oxidative stress, and apoptosis with strain-dependent differences in toxicity sensitivity, making it applicable for research on acute liver injury, drug-induced hepatotoxicity, and gastric mucosal damage.
体外研究
(In Vitro)

Propacetamol 通过经 CYP2E1 代谢生成毒性中间产物 N-乙酰对苯醌亚胺(NAPQI),耗竭肝内 GSH 并引发氧化应激、炎症反应及细胞凋亡,还会抑制 UGT1A1 表达、激活JNK/ERK通路,最终诱导急性肝损伤,其核心活性为模拟对乙酰氨基酚过量的毒理作用。

体内研究
(In Vivo)

Propacetamol (600-1200 mg/kg; i.p.; 单次注射) hydrochloride 诱导雄性 BALB/cByJNarl 小鼠发生严重急性肝损伤,且 1200 mg/kg 剂量具有致死性,会在 14 h 内导致 100% 的死亡率。
Propacetamol (1200-1400 mg/kg;腹腔注射;单次给药) 可在 BALB/c 小鼠中诱发急性致死性肝损伤,其中 1400 mg/kg 剂量会在 168 h 内导致 100%死亡率,1200 mg/kg 剂量则会使同一时期内的存活率降至 10%。
Propacetamol (1200-1800 mg/kg;腹腔注射;单剂量) 可在 C57BL/6 小鼠中诱导急性肝损伤,且该品系小鼠对其具有品系特异性耐受性;其中 1600 和 1800 mg/kg 剂量可在 168 h 内导致 100% 死亡率,同一时期内 1200 mg/kg 剂量可使存活率降至 50%。
Propacetamol (200 mg/kg; i.p.; single dose) 在乙酸诱导的持续性内脏痛小鼠模型中可产生显著的镇痛作用,表现为小鼠的腹部扭体反应减少。
Propacetamol (149-192 mg/kg,270-540 mg/kg; i.p.; 单剂量) 在采用甩尾急性热痛和热板急性热痛试验的小鼠中未产生显著的镇痛作用。
Propacetamol (125-500 mg/kg;灌胃;单次给药;ASA 给药前 30 分钟) 对雄性 Wistar 大鼠由 ASA 诱导的胃溃疡具有剂量依赖性胃保护作用:500 mg/kg 剂量可使溃疡面积减少 52.9%、胃黏膜 MDA 水平降低 66.9%,并通过维持升高的胃 UA 和谷胱甘肽水平来支持适应性抗氧化应答。

Animal Model: BALB/cByJNarl (six-week-old male, 20-22 g, acute liver injury induced by propacetamol injection)
Dosage: 600 mg/kg (acute liver injury induction); 1200 mg/kg (lethal model)
Administration: i.p.; single injection
Result: Induced significant acute liver injury, characterized by dark red discoloration of liver tissue, marked elevations in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, severe histopathological liver damage (cell vacuolization, membrane loss, nuclear disappearance, bleeding, and elevated histopathological scores), reduced hepatic glutathione (GSH) levels, increased thiobarbituric acid reactive substances (TBARS) and 3-nitrotyrosine (3-NT) levels, suppressed superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities, increased serum tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels, increased hepatic Bax expression and Bax/Bcl-2 ratio at 6 h post-injection, increased cleaved caspase-3 expression at 12 h post-injection, 83.00 ± 2.89% TUNEL-positive liver area at 18 h post-injection, increased hepatic cytochrome P450 2E1 (CYP2E1) expression, reduced UDP-glucuronosyltransferase family 1 member A1 (UGT1A1) expression, increased nuclear nuclear factor erythroid 2-related factor 2 (Nrf2) levels at 6 h post-injection, reduced Nrf2 and glutamate cysteine ligase catalytic subunit (GCLC) levels at 18 h post-injection, increased heme oxygenase 1 (HO-1) levels at 18 h post-injection, increased phosphorylated c-jun-N-terminal kinase (p-JNK)/JNK and phosphorylated extracellular signal-regulated kinase (p-ERK)/ERK ratios at 6 h post-injection, and increased hepatic receptor-interacting serine/threonine-protein kinase 1 (RIP1) expression at 6 h post-injection.\nCaused 100% mortality of all tested mice within 14 h post-injection without post-treatment.
Animal Model: BALB/cByJNarl (male, 5 weeks old, 20-22 g, acute liver injury induced by intraperitoneal propacetamol injection)
Dosage: 1200 mg/kg; 1400 mg/kg
Administration: i.p.; single dose
Result: Resulted in 10% survival at 168 h post-injection (1200 mg/kg).\nResulted in 0% survival at 168 h post-injection (1400 mg/kg).
Animal Model: C57BL/6JNarl (male, 5 weeks old, 20-22 g, acute liver injury induced by intraperitoneal propacetamol injection)
Dosage: 1200 mg/kg; 1400 mg/kg; 1600 mg/kg; 1800 mg/kg
Administration: i.p.; single dose
Result: Resulted in 50% survival at 168 h post-injection (1200 mg/kg).\nResulted in 40% survival at 168 h post-injection (1400 mg/kg).\nResulted in 0% survival at 168 h post-injection (1600 mg/kg).\nResulted in 0% survival at 168 h post-injection (1800 mg/kg).
Animal Model: Wistar (male, 240-270 g, ASA-induced gastric ulceration)
Dosage: 125 mg/kg; 250 mg/kg; 500 mg/kg
Administration: i.g.; single dose; 30 min before ASA
Result: Reduced ASA-induced gastric ulcer area by 22.0% (125 mg/kg), 38.5% (250 mg/kg), and 52.9% (500 mg/kg).\nReduced ASA-elevated gastric mucosal MDA levels by 48.4% (125 mg/kg), 56.3% (250 mg/kg), and 66.9% (500 mg/kg).\nElevated gastric mucosal UA levels above control values and significantly higher than the ASA-only group at 250 mg/kg and 500 mg/kg.\nDecreased gastric mucosal GSH and GSSG levels compared to the ASA-only group but remained significantly higher than control values.\nCaused gastric mucosa to appear almost normal, with only occasional bending of superficial epithelium and focal desquamation observed.\nReduced plasma MDA levels by a slight, non-significant 1.5% at 500 mg/kg compared to the ASA-only group.\nElevated plasma UA levels above control values, increasing by 19.8% (250 mg/kg) and 26.7% (500 mg/kg) compared to the ASA-only group.
性状 固体
颜色 White to light yellow

化学信息

分子量 300.78
分子式 C14H21ClN2O3
CAS No. 66532-86-3
别名 盐酸丙帕他莫

储存&溶解度

储存方式

4°C, stored under nitrogen, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 200 mg/mL (664.92 mM; 超声助溶)

DMSO 中的溶解度 : 25 mg/mL (83.11 mM; 超声助溶 (<80°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM3.3246 mL16.6229 mL33.2458 mL83.1145 mL
5 mM0.6649 mL3.3246 mL6.6492 mL16.6229 mL
10 mM0.3325 mL1.6623 mL3.3246 mL8.3114 mL
15 mM0.2216 mL1.1082 mL2.2164 mL5.5410 mL
20 mM0.1662 mL0.8311 mL1.6623 mL4.1557 mL
25 mM0.1330 mL0.6649 mL1.3298 mL3.3246 mL
30 mM0.1108 mL0.5541 mL1.1082 mL2.7705 mL
40 mM0.0831 mL0.4156 mL0.8311 mL2.0779 mL
50 mM0.0665 mL0.3325 mL0.6649 mL1.6623 mL
60 mM0.0554 mL0.2770 mL0.5541 mL1.3852 mL
80 mM0.0416 mL0.2078 mL0.4156 mL1.0389 mL
H2O100 mM0.0332 mL0.1662 mL0.3325 mL0.8311 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础